

Table A2. Association between GGH immunostaining results and prostate cancer phenotype in ERG fusion **positive** tumours.

Parameter	n evaluable	GGH (%)			p value
		Negative	Low	High	
All cancers	4,049	5.9	46.9	47.2	
Tumour stage					0.0104
pT2	2,411	5.4	48.5	46.1	
pT3a	1,072	6.2	43.2	50.7	
pT3b-pT4	551	8.0	46.8	45.2	
Gleason grade					0.1031
≤3+3	842	7.8	47.5	44.7	
3+4	2,176	5.3	47.4	47.2	
3+4 Tert.5	126	4.8	39.7	55.6	
4+3	350	5.7	44.3	50.0	
4+3 Tert.5	218	4.6	46.3	49.1	
≥4+4	135	8.9	49.6	41.5	
Lymph node metastasis					<0.0001
N0	2,317	5.4	44.3	50.3	
N+	259	11.6	53.7	34.7	
Preoperative PSA level (ng/ml)					0.0015
<4	551	4.2	48.6	47.2	
4-10	2,473	5.5	45.9	48.6	
10-20	731	7.3	47.3	45.4	
>20	249	10.4	51.8	37.8	
Surgical margin					0.5931
Negative	3,174	5.8	46.8	47.4	
Positive	800	6.4	48.1	45.5	